The rollout of GLP-1 generics in India is creating a clear divergence between pharma and consumer sectors. While the opportunity for drugmakers is becoming more tangible with falling prices and rising access, the impact on FMCG remains longer-dated—and more about valuations than earnings.
JPMorgan, in its latest note on India consumer, flags that GLP-1 drugs are 'not an imminent disruption,' estimating less than 1% revenue impact for food and beverage companies even by FY28–30. In contrast, Morgan Stanley sees generics as a structural inflection point for pharma, marking the shift of GLP-1 from a niche therapy to a mass-market category.
With the patent expiry of semaglutide, the GLP-1 market has already seen the entry of nearly 40 generic players, triggering a steep 70–80% price correction, according to Morgan Stanley. This has significantly expanded the addressable market. Citing IQVIA data, the brokerage estimates the domestic GLP-1 opportunity could scale to around Rs 9,000 crore by FY30, while also contributing 1–2% incremental growth to the Indian Pharma Market (IPM).
On stock preferences, Morgan Stanley highlights Sun Pharma and Dr. Reddy's Laboratories as best placed to gain share, given their scale, manufacturing capabilities, and backward integration. It also flags potential upside from Cipla, where its tirzepatide play (Yurpeak) could surprise positively as adoption ramps up.
However, the near-term phase is expected to be competitive. FY27 is likely to be focused on brand-building and market capture, which could keep margins subdued initially.
ALSO READ: Ozempic Copies At $14 In India As Generic Glp-1 Era Starts
FMCG: Earnings Stable, Multiples Vulnerable
On the consumer side, JPMorgan draws a clear distinction between behavioural change and financial impact. While GLP-1 adoption could gradually alter consumption habits—particularly toward lower-calorie, protein- and fibre-rich foods—the earnings effect is expected to remain limited in the foreseeable future.
The key constraint remains affordability. Even with generics, therapy costs are still high relative to average incomes, restricting usage largely to urban, higher-income cohorts. That said, the brokerage warns that valuations could come under pressure earlier than earnings, especially as markets begin to price in long-term shifts in consumption patterns.
It points to global precedents, where staples companies have already seen multiple compression amid slowing volumes, rising competition, and changing dietary preferences.
Stocks in Focus
JPMorgan flags a set of Indian consumer names where the GLP-1 narrative could increasingly influence investor debate. These include Nestlé India, Britannia Industries, Varun Beverages (VBL), United Breweries, United Spirits, and Jubilant FoodWorks.
The common thread across these companies is their exposure to discretionary or “indulgence-led” consumption—categories that could see gradual moderation if GLP-1 adoption scales meaningfully over time.
However, the impact is unlikely to be uniform. Companies that pivot toward health-focused portfolios, smaller portion sizes, and functional nutrition could offset risks and even tap into emerging demand trends.
For now, pharma offers a more visible earnings and growth trigger, supported by pricing tailwinds and expanding penetration. FMCG, on the other hand, remains a long-duration story, where the impact is gradual but could influence terminal growth assumptions.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.